Dr Mark Spyvee is an organic chemist who has been actively involved in the conception and development of 16 novel compounds, is co-author of 56 publications and cited as inventor on 14 provisional patent applications since 2015; with a total of 26 published patents since 1992. Mark’s chemistry training includes a Doctorate at the University of Oxford (with Prof. Sir Jack Baldwin, FRS), and a Post-doctoral Fellowship at UT Austin (with Prof. Phil Magnus, FRS).
Early in his career working at ICI Agrochemicals (1988-1992), Mark engaged in several insecticidal and antifungal programs at ICI Agrochemicals including the $Billion product azoxystrobin. From 1998 to 2012 he led multidisciplinary teams at a large Japanese pharma company, Eisai, throughout early lead finding, medicinal chemistry and preclinical development, yielding candidates for rheumatoid arthritis, oncology and immuno-oncology. At Eisai he was Director of Medicinal Chemistry and co-headed the Immunology Group spanning sites in the US, UK and Japan. Mark was also responsible for the management of programs spanning rheumatoid arthritis, lupus, psoriasis, sepsis, nociceptive pain, multiple sclerosis, endometriosis, ulcerative colitis and Crohn’s disease. Mark also has fours years experience as Vice President of Business Development from Asian CRO/CMO Sai Life Sciences (2012-2016) where managed a portfolio of over 30 biotech and pharma clients.
More recently, Mark founded an R&D consulting firm in 2013 offering drug discovery and development guidance by providing key services that include medicinal chemistry problem solving, drug design, value proposition assessment, due diligence, fund raising, patent strategy and document preparation, CRO/CMO management and project leadership. Over the last 4 years Mark has driven 3 projects through candidate nomination and preclinical development, and progressed lead optimization for an additional 6 projects.